Results 21 to 30 of about 1,142,872 (298)

Efficacy and safety of vedolizumab in ulcerative colitis in patients from Asian countries in the GEMINI 1 study [PDF]

open access: yesIntestinal Research, 2021
Background/Aims The efficacy and safety of vedolizumab in moderate to severely active ulcerative colitis (UC) have been demonstrated in the GEMINI 1 study (NCT00783718).
Choon Jin Ooi   +7 more
doaj   +1 more source

Experience with FLT3 Inhibitor Midostaurin in Newly Diagnosed Acute Myeloid Leukemia Patients

open access: yesTurkish Journal of Internal Medicine, 2021
Introduction With the introduction of FLT3 inhibitors in recent years, the presence of FLT3 mutation in newly diagnosed acute myeloid leukemia (AML) patients has become more important.
Mehmet Baysal, Nihan Alkis, Serap Baysal
doaj   +1 more source

Glutamine for induction of remission in Crohn's disease [PDF]

open access: yesCochrane Database of Systematic Reviews, 2016
Crohn's disease is a chronic relapsing condition of the alimentary tract with a high morbidity secondary to bowel inflammation. Glutamine plays a key role in maintaining the integrity of the intestinal mucosa and has been shown to reduce inflammation and disease activity in experimental models of Crohn's disease.To evaluate the efficacy and safety of ...
Akobeng, Anthony   +2 more
openaire   +2 more sources

Induction therapy for adults with acute lymphoblastic leukemia: results of more than 1500 patients from the international ALL trial: MRC UKALL XII/ECOG E2993 [PDF]

open access: yes, 2005
The international acute lymphoblastic leukemia (ALL) study was designed to prospectively define the optimal therapy for adults 60 years of age or younger with newly diagnosed ALL.
Burnett, Alan Kenneth   +53 more
core   +1 more source

REMISSION RATE OF PRE-B ALL (ACUTE LYMPHOBLASTIC LEUKEMIA) AFTER INDUCTION CHEMOTHERAPY FOLLOWING UNITED KINGDOM ACUTE LYMPHOBLASTIC LEUKAEMIA 2011 (UKALL 2011) TRIAL PROTOCOL

open access: yesPakistan Armed Forces Medical Journal, 2021
Objective: To find out the rate of remission of Pre-B Acute Lymphoblastic Leukaemia in children at the end of induction treatment with United Kingdom Acute Lymphoblastic Leukaemia (UKALL) 2011 chemotherapy protocol.
Hafiz Muhammad Murtaza   +2 more
doaj   +1 more source

Etrolizumab for induction of remission in ulcerative colitis

open access: yesCochrane Database of Systematic Reviews, 2015
Etrolizumab (rhuMAb beta7) is an anti-integrin that selectively targets the β7 subunits of the α4β7 and αEβ7 integrins, which are involved in the pathogenesis of ulcerative colitis.The objectives of this review were to assess the efficacy and safety of etrolizumab for induction of remission in ulcerative colitis.We searched PubMed, MEDLINE, EMBASE, and
Greg, Rosenfeld   +3 more
openaire   +3 more sources

Predictors of remission with etanercept-methotrexate induction therapy and loss of remission with etanercept maintenance, reduction, or withdrawal in moderately active rheumatoid arthritis: results of the PRESERVE trial

open access: yesArthritis Research & Therapy, 2018
Background The aim was to analyze characteristics that predict remission induction and subsequent loss of remission in patients with moderately active rheumatoid arthritis (RA) who received full-dose combination etanercept plus methotrexate induction ...
Josef S. Smolen   +4 more
doaj   +1 more source

Probiotics for induction of remission in Crohn's disease [PDF]

open access: yesCochrane Database of Systematic Reviews, 2008
Crohn's disease has a high morbidity and there is no known cure. Current treatments have multiple side effects and an effective treatment with minimal side effects is desired. Probiotics have been proposed as such a treatment but their efficacy is undetermined.
Andrew D, Butterworth   +2 more
openaire   +2 more sources

The Role of Mycophenolate Mofetil for the Induction of Remission in ANCA-Associated Vasculitis: A Meta-Analysis

open access: yesFrontiers in Medicine, 2021
Objectives: The successful introduction of mycophenolate mofetil (MMF) as a treatment for renal allograft reduced the incidence of acute rejection. The inspiring effects obtained by the MMF have led to an evaluation of its therapeutic potency on ANCA ...
Anji Xiong   +11 more
doaj   +1 more source

Adalimumab for induction of remission in Crohn's disease

open access: yesCochrane Database of Systematic Reviews, 2017
Adalimumab is an IgG1 monoclonal antibody that targets and blocks tumor necrosis factor-alpha, a pro-inflammatory cytokine involved in the pathogenesis of Crohn's disease (CD). A significant proportion of people with CD fail conventional therapy or therapy with biologics or develop significant adverse events.
Mohamad, Abbass   +7 more
openaire   +4 more sources

Home - About - Disclaimer - Privacy